MTD vs. SNY: Mettler-Toledo vs. Sanofi Stock Comparison
How do Mettler-Toledo (MTD) and Sanofi (SNY) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Mettler-Toledo (MTD) and Sanofi (SNY) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but MTD is classified in Life Sciences Tools & Services while SNY is classified in Pharmaceuticals.
Mettler-Toledo (MTD) trades as ordinary local shares, while Sanofi (SNY) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.
| Profile Item | MTD | SNY |
|---|---|---|
| Name | Mettler-Toledo International Inc. | Sanofi ADR |
| Country/Region | Switzerland | France |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Life Sciences Tools & Services | Pharmaceuticals |
| GICS Sub-Industry | Life Sciences Tools & Services | Pharmaceuticals |
| Market Capitalization | 34.25 billion USD | 112.71 billion USD |
| Currency | USD | USD |
| Exchange | NYSE | Nasdaq |
| Listing Date | November 14, 1997 | July 1, 2002 |
| Security Type | Common Stock | ADR |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | MTD | SNY |
|---|---|---|
| Total Return (1Y) | 21.58% | 2.73% |
| Total Return (3Y, Annualized) | 19.54% | 6.89% |
| Total Return (5Y, Annualized) | 2.36% | 3.16% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | MTD | SNY |
|---|---|---|
| Volatility (1Y, Annualized) | 31.70% | 23.60% |
| Beta (5Y) | 1.15 | 0.28 |
| Max Drawdown (5Y) | -43.47% | -33.52% |
| Avg. Volume (3M) | 197.80K | 3.29M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | MTD | SNY |
|---|---|---|
| Sharpe Ratio (1Y) | 0.55 | -0.07 |
| Sortino Ratio (1Y) | 0.75 | -0.10 |
Profitability
ROE (TTM)
Capital efficiency shows on one side only: Sanofi (SNY) earns 5.72% on shareholders’ equity, ranked against its industry; Mettler-Toledo (MTD) has no ROE this period.
MTD
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 109.18%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
- MTD
- --
SNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.72%
- Max
- 109.18%
- Q3
- 6.23%
- SNY
- 5.72%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Mettler-Toledo (MTD) at 22.25% keeps the most of each sales dollar — above its industry’s net margin range — and Sanofi (SNY) at 8.20% also retains a top-quartile share.
MTD
Pharmaceuticals, Biotechnology & Life Sciences industry group
22.25%
- MTD
- 22.25%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
SNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
8.20%
- Max
- 18.05%
- SNY
- 8.20%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Both Mettler-Toledo (MTD) at 28.70% and Sanofi (SNY) at 30.89% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.
MTD
Pharmaceuticals, Biotechnology & Life Sciences industry group
28.70%
- Max
- 83.12%
- MTD
- 28.70%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
SNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
30.89%
- Max
- 83.12%
- SNY
- 30.89%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | MTD | SNY |
|---|---|---|
| ROE (TTM) | -- | 5.72% |
| ROA (TTM) | 20.09% | 5.31% |
| Net Margin (TTM) | 22.25% | 8.20% |
| Operating Margin (TTM) | 28.70% | 30.89% |
| Gross Margin (TTM) | 59.16% | 73.68% |
Growth
Revenue Growth
Both Mettler-Toledo (MTD) at 3.98% and Sanofi (SNY) at 5.49% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.
EPS Growth
Both Mettler-Toledo (MTD) at 3.88% and Sanofi (SNY) at 39.43% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.
Growth Metrics
| Metric | MTD | SNY |
|---|---|---|
| Revenue Growth (YoY) | 3.98% | 5.49% |
| Revenue Growth (3Y CAGR) | 0.90% | 4.82% |
| EPS Growth (YoY) | 3.88% | 39.43% |
| EPS Growth (3Y CAGR) | 3.06% | 6.02% |
Financial Strength
Current Ratio (MRQ)
Both Mettler-Toledo (MTD) at 1.10 and Sanofi (SNY) at 1.12 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.
MTD
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.10
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- MTD
- 1.10
- Min
- 0.10
SNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.12
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- SNY
- 1.12
- Min
- 0.10
Debt / Equity (MRQ)
Sanofi (SNY) at 0.27 is near its industry mid-range for debt-to-equity ratio, while Mettler-Toledo (MTD) at 26.06 sits above its benchmark range, pointing to a heavier debt load relative to equity.
MTD
Pharmaceuticals, Biotechnology & Life Sciences industry group
26.06
- MTD
- 26.06
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
SNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.27
- Max
- 1.42
- Q3
- 0.65
- SNY
- 0.27
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | MTD | SNY |
|---|---|---|
| Current Ratio (MRQ) | 1.10 | 1.12 |
| Debt / Equity (MRQ) | 26.06 | 0.27 |
| Net Debt / EBITDA | 1.58 | 0.96 |
Dividends
Dividend Yield (TTM)
Neither Mettler-Toledo (MTD) nor Sanofi (SNY) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
MTD
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- MTD
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
SNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- SNY
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Sanofi (SNY) reports payout ratio above 100% at 119.86%, meaning dividends exceeded current-period earnings; Mettler-Toledo (MTD) pays no dividend (payout 0.00%).
MTD
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- MTD
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
SNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
119.86%
- SNY
- 119.86%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | MTD | SNY |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 119.86% |
Valuation
P/E Ratio (TTM)
Both Mettler-Toledo (MTD) at 37.38 and Sanofi (SNY) at 23.40 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.
MTD
Pharmaceuticals, Biotechnology & Life Sciences industry group
37.38
- Max
- 85.34
- Q3
- 43.46
- MTD
- 37.38
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
SNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
23.40
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- SNY
- 23.40
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
Sanofi (SNY) at 2.21 sits in the cheaper P/S ratio quartile while Mettler-Toledo (MTD) at 8.16 prices around its industry’s middle — SNY costs less per dollar of sales, though read it alongside growth and margins.
MTD
Pharmaceuticals, Biotechnology & Life Sciences industry group
8.16
- Max
- 58.18
- Q3
- 25.77
- MTD
- 8.16
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
SNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.21
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- Q1
- 3.01
- SNY
- 2.21
- Min
- 0.01
P/B Ratio (MRQ)
Sanofi (SNY) at 1.38 sits in the lower P/B ratio quartile relative to book while Mettler-Toledo (MTD) at 442.71 prices above its industry range — a wide valuation gap against assets.
MTD
Pharmaceuticals, Biotechnology & Life Sciences industry group
442.71
- MTD
- 442.71
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
SNY
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.38
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- SNY
- 1.38
- Min
- -5.59
Valuation Metrics
| Metric | MTD | SNY |
|---|---|---|
| P/E Ratio (TTM) | 37.38 | 23.40 |
| P/S Ratio (TTM) | 8.16 | 2.21 |
| P/B Ratio (MRQ) | 442.71 | 1.38 |
| Free Cash Flow Yield (TTM) | 1.97% | 7.17% |